U.S. Food and Drug Administration Statements About Transvaginal Mesh and Changes in Apical Prolapse Surgery

OBJECTIVE:To assess the effects of the U.S. Food and Drug Administration (FDA) safety communication and the reclassification of transvaginal mesh to a class III device on national trends in the treatment of apical prolapse.METHODS:A retrospective cohort study of surgical cases from 2008 to 2017 from